Q4 Earnings Forecast for TSE:GUD Issued By Raymond James

Knight Therapeutics Inc. (TSE:GUD) – Research analysts at Raymond James issued their Q4 2024 earnings estimates for shares of Knight Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. Raymond James analyst R. Sarugaser expects that the company will earn $0.01 per share for the quarter. Raymond James currently has a “Moderate Buy” rating on the stock. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Raymond James also issued estimates for Knight Therapeutics’ Q1 2025 earnings at $0.00 EPS and Q3 2025 earnings at $0.00 EPS.

Other analysts have also recently issued research reports about the company. Stifel Nicolaus upgraded Knight Therapeutics from a “hold” rating to a “buy” rating and upped their price target for the stock from C$5.75 to C$6.75 in a research note on Tuesday, August 13th. Stifel Canada upgraded Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th.

Knight Therapeutics Trading Down 0.6 %

Shares of TSE:GUD opened at C$5.19 on Friday. The company has a current ratio of 3.41, a quick ratio of 1.79 and a debt-to-equity ratio of 7.62. The stock has a market capitalization of C$525.28 million, a PE ratio of -25.95, a P/E/G ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics has a 1 year low of C$5.07 and a 1 year high of C$6.23. The firm has a fifty day moving average price of C$5.71 and a 200 day moving average price of C$5.73.

Insiders Place Their Bets

In related news, Senior Officer Amal Khouri sold 5,000 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of C$5.78, for a total transaction of C$28,919.00. Also, insider Sime Armoyan sold 300,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of C$6.13, for a total transaction of C$1,839,000.00. Company insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.